Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Assets: 2012-2025

Historic Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.6 billion.

  • Ptc Therapeutics' Assets rose 43.50% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 43.50%. This contributed to the annual value of $1.7 billion for FY2024, which is 10.06% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Assets is $2.6 billion, which was up 0.36% from $2.6 billion recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Assets high stood at $2.7 billion for Q1 2025, and its period low was $1.3 billion during Q3 2023.
  • For the 3-year period, Ptc Therapeutics' Assets averaged around $1.9 billion, with its median value being $1.8 billion (2024).
  • In the last 5 years, Ptc Therapeutics' Assets decreased by 25.83% in 2023 and then spiked by 48.38% in 2025.
  • Ptc Therapeutics' Assets (Quarterly) stood at $1.9 billion in 2021, then dropped by 11.99% to $1.7 billion in 2022, then grew by 11.14% to $1.9 billion in 2023, then fell by 10.06% to $1.7 billion in 2024, then surged by 43.50% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q3 2025, $2.6 billion for Q2 2025, and $2.7 billion during Q1 2025.